[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hereditary-breast-and-ovarian-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hereditary-breast-and-ovarian-cancer":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,92,119,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":69,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100289631","familial-investigations-of-childhood-cancer-predisposition-100289631",false,"NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.\n\nDEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:\n\nIn this protocol, the definition of \"Familial Cancer\" is met if any of the following is present:\n\n* An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR\n* An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR\n* An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR\n* An individual with a congenital cancer diagnosed before 6 months of age; OR\n* An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age\n\nº Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.\n\nINCLUSION CRITERIA:\n\n* An individual who meets this protocol's definition of \"Familial Cancer,\" as above.\n* Biologic relatives of an individual meeting this protocol's definition of \"Familial Cancer,\" who are either affected or unaffected by cancer.\n\nEXCLUSION CRITERIA:\n\n* An inability or unwillingness of the research participant or his\u002Fher legally authorized representative (LAR) to provide written informed consent.\n* The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.","ALL",{"count":18,"type":19},1500,"ESTIMATED","OBSERVATIONAL","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.\n\nWhile it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.\n\nThe purpose of this protocol is to identify novel cancer predisposing genes and\u002For genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.\n\nPRIMARY OBJECTIVE:\n\n* Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.\n\nSECONDARY OBJECTIVE:\n\n* Identify novel cancer predisposing genes and\u002For genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.",[23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68],"Acute Leukemia","Adenomatous Polyposis","Adrenocortical Carcinoma","AML","BAP1 Tumor Predisposition Syndrome","Carney Complex","Choroid Plexus Carcinoma","Constitutional Mismatch Repair Deficiency Syndrome","Diamond-Blackfan Anemia","DICER1 Syndrome","Dyskeratosis Congenita","Emberger Syndrome","Familial Acute Myeloid Leukemia","Familial Adenomatous Polyposis","Fanconi Anemia","Familial Cancer","Familial Wilms Tumor","Familial Neuroblastoma","GIST","Hereditary Breast and Ovarian Cancer","Hereditary Paraganglioma-Pheochromocytoma Syndrome","Hodgkin Lymphoma","Juvenile Polyposis","Li-Fraumeni Syndrome","Lynch Syndrome","MDS","Melanoma Syndrome","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Neuroblastoma","Neurofibromatosis Type 1","Neurofibromatosis Type II","Nevoid Basal Cell Carcinoma Syndrome","Non Hodgkin Lymphoma","Noonan Syndrome and Other Rasopathy","Overgrowth Syndromes","Pancreatic Cancer","Peutz-Jeghers Syndrome","Pheochromocytoma\u002FParaganglioma","PTEN Hamartoma Tumor Syndrome","Retinoblastoma","Rhabdoid Tumor Predisposition Syndrome","Rhabdomyosarcoma","Rothmund-Thomson Syndrome","Tuberous Sclerosis","Von Hippel-Lindau Disease",[70,71,72,73,74,75,76,77,78],"Familial cancer","Genetic predisposition","Heritable disease","Cancer risk","Genome analysis","Genetic modifiers","Next generation sequencing (NGS)","Genetic counseling","DNA","RECRUITING","2026-06-15",{"date":82,"type":83},"2026-06-17","ACTUAL",{"date":85,"type":83},"2017-04-06",{"date":87,"type":19},"2037-03-31",{"name":89,"class":90},"St. Jude Children's Research Hospital","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":102,"conditions":103,"keywords":104,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100295306","cascade-genetic-testing-for-hereditary-breastovarian-cancer-and-lynch-syndrome-in-switzerland-100295306","NCT03124212","Cascade Genetic Testing for Hereditary Breast\u002FOvarian Cancer and Lynch Syndrome in Switzerland","CASCADE","Inclusion Criteria:\n\n1. Carrier of a mutation associated with HBOC or LS\n2. Have at least one living blood relative\n3. Men and women\n4. 18 years old and older\n5. Mentally and physically able to provide informed consent\n6. Can read and speak German or French or Italian or English\n7. Currently living in Switzerland.\n\nExclusion Criteria:\n\n1. Carriers of unclassified variants (VUS) in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes\n2. Not living in Switzerland\n3. Patients who are critically ill and cannot complete the CASCADE survey\n4. Participants who are institutionalized (e.g., nursing homes) or incarcerated","18 Years",{"count":101,"type":19},700,"Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer cases in Switzerland and affect more than 12,000 individuals annually. Several hundred of these patients are likely to carry known genetic mutations associated with HBOC or LS. Genetic testing for hereditary susceptibility to cancer can prevent many cancer deaths through early identification and engagement in high-risk management care that involves intensive surveillance, chemoprevention and\u002For prophylactic surgery. However, current rates of genetic testing indicate that many Swiss mutation carriers and their family members do not use cancer genetic services (counseling and\u002For testing), either due to lack of coordination of care or due to lack of communication about the mutation among family members.\n\nCascade screening identifies and tests family members of a known mutation carrier. It determines whether asymptomatic family members are carriers of the identified mutation and proposes management options to reduce harmful outcomes. Robust evidence of basic science and descriptive population-based studies in Switzerland support the necessity of cascade screening for HBOC and LS. However, translation of this knowledge into public health interventions is lacking.\n\nSpecific Aims of the CASCADE study are:\n\n1. Survey Index Patients diagnosed with HBOC or LS from clinic-based genetic testing records and determine their cancer status and surveillance practices; needs for coordination of medical care; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to serve as advocates for cancer genetic services for blood relatives.\n2. Survey first- and second-degree relatives, and first cousins identified from pedigrees and\u002For family history records of HBOC and LS Index Patients and determine their cancer and mutation status; cancer surveillance practices; needs for coordination of medical care; barriers and facilitators to using cancer genetic services; psychosocial needs; patient-provider and patient-family communication needs; quality of life; willingness to participate in a study designed to increase use of cancer genetic services.\n3. Explore the influence of patient-provider communication about genetic cancer risk on patient-family communication and the acceptability of a family-based communication, coping, and decision support intervention with focus group(s) of mutation carriers and blood relatives.",[42,47],[105,106,107,108],"mutation carrier","blood relative","genetic testing","family-based cohort","2026-05-10",{"date":111,"type":83},"2026-05-13",{"date":113,"type":83},"2017-04-01",{"date":115,"type":19},"2035-01-31",{"name":117,"class":90},"University of Basel",9,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":127,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":129,"studyType":20,"phases":4,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":147},"100232367","triple-negative-breast-cancer-and-germline-hereditary-breast-and-ovarian-cancer-mutation-carrier-registry-100232367","NCT02302742","Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry","PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations","PROGECT","Inclusion criteria include:\n\nTriple Negative Breast Cancer\n\n* ER\u002FPR \\\u003C10% and HER negative per current ASCO\u002FCAP guidelines\n* Stages I-IV\n* Any age at diagnosis\n* Patient must be within 5 years of diagnosis\n* Eligible regardless of genetic testing status\n* Genetic testing recommended for patients meeting NCCN and Medicare guidelines\n\nAND\u002FOR\n\nGermline mutation Carriers\n\n* Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type\u002Fsite of cancer\n* Healthy patients harboring mutations also eligible\n* There is no time limit from the time of diagnosis of cancer and enrollment.\n* Eligible regardless of personal history of cancer\n\nExclusion Criteria include:\n\nTriple Negative Breast Cancer -Patient is not within five years of diagnosis\n\nGermline mutation Carriers:\n\n-Patient only carries a HBOC mutation that is classified as \"polymorphism\" of \"favor polymorphism\"",true,{"count":18,"type":19},"10 Years","PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).",[132,42],"Breast Cancer",[134,135,42,136,137],"Triple Negative Breast Cancer","TNBC","HBOC","Prospective Registry","2025-09-30",{"date":140,"type":83},"2025-10-06",{"date":142,"type":83},"2011-03-22",{"date":144,"type":19},"2026-12",{"name":146,"class":90},"University of Kansas Medical Center",11,{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":127,"sex":155,"minAge":99,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":158,"phases":159,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":177},"100449294","contigo---a-narrative-intervention-to-enhance-genetic-counseling-and-testing-100449294","NCT05130606","CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing","Testing a Narrative Intervention to Enhance Genetic Counseling and Testing","Inclusion Criteria:\n\nAim 1 and 2.\n\n* Self-identify as a Latina woman\n* Be 18 years old or older\n* Be able to provide informed consent\n* Be fluent in Spanish\n* Meet NCCN criteria to be considered for genetic cancer risk assessment for HBOC, whether by a personal history of cancer or family history of cancer\n* No previous participation in genetic counseling or testing for hereditary breast and ovarian cancer risk\n* No other family members are participating in this study\n* Have not participated in any previous studies involving interventions about HBOC or GCT\n\nAim 3.\n\n* Be 18 years old or older\n* Be fluent in English or Spanish\n* Have a role in the partner community clinic as either a) full-time or part-time employee b) intern c) volunteer\n\nExclusion Criteria:\n\n\\-","FEMALE",{"count":157,"type":19},332,"INTERVENTIONAL",[160],"NA","This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening tool.\n\nIn this study, the investigators aim to evaluate the efficacy of a culturally targeted video previously developed by the research team vs. a Spanish-language fact sheet from an established group on enhancing genetic counseling and testing uptake and psychosocial outcomes in Latina women at risk for hereditary breast and ovarian cancer.\n\nThe investigators will test the video's efficacy while also gathering data on the implementation and future sustainability of using the Risk Screening Tool (RST) and video in community clinics.",[42],[164,165,166,167],"Breast cancer","Ovarian cancer","Hereditary cancer","Latinas","2025-08-22",{"date":170,"type":83},"2025-08-28",{"date":172,"type":83},"2021-06-01",{"date":174,"type":19},"2025-12-31",{"name":176,"class":90},"Georgetown University",2]